2 Beaten-Down Stocks Worth Buying and Holding for the Next Decade

The article identifies Netflix and Intuitive Surgical as potential recovery opportunities despite recent headwinds. Netflix viewing hours rose just 2% year over year in the first half, while its sports-rights and streaming-hub opportunities could support engagement and monetization. Intuitive Surgical’s da Vinci installed base is nearing 12,000 devices, and fewer than 8% of relevant soft-tissue procedures are performed robotically; the stock is down about 30% this year, with competition and weaker-than-expected margins remaining risks.

Analysis

The key distinction is monetization risk versus adoption risk. NFLX’s engagement problem makes incremental sports rights a potentially expensive retention tool: rights costs can rise before viewing hours, ad yield, or churn improve. Turning the app into a hub could deepen engagement, but revenue sharing and customer ownership may dilute economics; treat that idea as optionality, not a forecast. The near-term test is whether viewing and ad monetization improve without a material step-up in content costs.

ISRG’s new rivals are not automatically a thesis break. Broader availability of robotic platforms could help normalize adoption, while hospitals’ multi-vendor leverage may pressure pricing and slow placements. ISRG’s installed base and training ecosystem support switching costs, but do not guarantee that da Vinci 5’s higher capabilities translate into procedures or durable margins. The important 1–3 month evidence is procedure growth, system placements, and margin trajectory; over 6–18 months, watch whether adoption expands beyond existing users and whether new entrants win meaningful utilization.

Contrarian angle: the article treats a large addressable market and ecosystem as sufficient recovery arguments. Neither resolves execution: NFLX must convert attention into profitable engagement; ISRG must convert product investment into utilization while defending economics. No valuation or current price data are supplied, so avoid treating either as demonstrably cheap. ISRG has the clearer measurable operating thesis; NFLX is more dependent on unproven strategic execution.

Key Decisions for Investors

• Prefer ISRG over NFLX for a measured, staged long: add only as operating data confirms procedure growth alongside stabilization or improvement in margins. Reassess if placements weaken or margin pressure persists without evidence of higher utilization.
• Do not chase NFLX on sports-rights or hub speculation. Keep it on a catalyst watchlist; require improving engagement and ad monetization relative to content-cost growth before adding. A rising rights burden without those gains falsifies the recovery case.
• Avoid an outright short in MDT or JNJ based solely on their launches. Consider an ISRG-versus-medtech-competitors relative-value position only after verifying competitor placements, utilization, and pricing; broadening adoption could benefit the category rather than displace ISRG.
• For both names, size positions against execution risk rather than the article’s characterization of recent share-price declines; verify current valuation, guidance, and operating trends before entry.